Patients Coming Off Weight-Loss Injections Regain Weight at a Quadrupled Rate Than Those on Conventional Diets

A recent study indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs.

Published data in a leading health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.

"Individuals buying these medications should be informed of the risk of rapid rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.

Such speed of recovery implies a reversion to pre-treatment mass within about a year and a half.

Analyzing Treatments

The analysis, which reviewed dozens of studies involving thousands of participants, compared the results of the injectable medications with conventional dieting.

Scientists note that people who shed pounds through diet and exercise usually have a slower weight regain—around 100 grams monthly—post-intervention.

Understanding the Rapid Regain

Doctors propose the mechanism of the jabs explains the amplified rebound.

These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates appetite.

"Long-term administration of GLP-1 levels several times higher than normal might result in the body to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.

"Stopping of this medication means appetite is no longer kept in check, making binge eating much more probable."

A Lifelong Condition?

The NHS recommend the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Many experts argue that, considering the significant potential of weight regain, the therapy should be considered ongoing.

This perspective is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," akin to managing diseases like high blood pressure.

Patient Experiences

Individuals who have come off the medication describe a sudden return of cravings.

"It felt as if a switch flipping and I was suddenly extremely hungry," said one woman.

This difficulty is exacerbated if patients have not established sustainable dietary or behavioural changes during therapy.

Significant Use

Survey data show that millions of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.

• Use is greater among females than males.
• The middle-aged demographic shows the greatest level of interest.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

In conclusion, experts stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone solution and long-term success relies on combined lifestyle management.